
Liquidia Corporation (LQDA)
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
시가총액
$1.3B
수익
$14M
P/E 비율
N/A
주가순자산비율
11.98
부채자본비율
1.58
배당 수익률
0.00%
마지막 업데이트: June 10 at 21:46:32